Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01740388 · ClinicalTrials.gov registry record · Phase 3
Clinical and Microbial Efficacy of Besifloxacin Ophthalmic Suspension, 0.6% in the Treatment of Bacterial Conjunctivitis
A Phase 3 study, sponsored by Bausch & Lomb Incorporated.
- Terminated
- Registry status
- Phase 3
- Development phase
- 136
- Enrollment target
NCT01740388 is a Phase 3 study that was terminated before completion, run by Bausch & Lomb Incorporated. The registered enrollment target is 136 participants.
The verdict
NCT01740388, a Phase 3 study, was terminated before completion, sponsored by Bausch & Lomb Incorporated.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 136 participants
- Enrollment target
Study Summary
To evaluate the clinical and microbial efficacy of besifloxacin ophthalmic suspension, 0.6% (Besifloxacin) administered BID for 3 days compared to vehicle in the treatment of bacterial conjunctivitis.
Interventions
- DRUG Vehicle
- DRUG Besifloxacin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 136 participants |
| Start Date | 2013-02 |
| Est. Completion | 2013-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01740388
The ClinicalTrials.gov registry entry for NCT01740388 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 136 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bausch & Lomb Incorporated, which has 174 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Vehicle is the first listed.
NCT01740388 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01740388 about?
NCT01740388 is a clinical study titled "Clinical and Microbial Efficacy of Besifloxacin Ophthalmic Suspension, 0.6% in the Treatment of Bacterial Conjunctivitis". To evaluate the clinical and microbial efficacy of besifloxacin ophthalmic suspension, 0.6% (Besifloxacin) administered BID for 3 days compared to vehicle in the treatment of bacterial conjunctivitis.
What is the current status of trial NCT01740388?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 136 participants. The study started on 2013-02. Estimated completion is 2013-11.
What interventions are being tested in trial NCT01740388?
The interventions under investigation include: Vehicle (DRUG), Besifloxacin (DRUG).
Who is sponsoring clinical trial NCT01740388?
This trial is sponsored by Bausch & Lomb Incorporated, which has 174 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.